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• 310	μl	DNA		 1. Heat	lid	to	110	°C	2. 95	°C	for	15	minutes	3. 35	cycles	a. 94	°C	for	1	minute	b. 60	°C	for	1	minute	c. 72	°C	for	1	minute	4. 72	°C	for	5	minutes	5. Store	at	8	°C		
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controls,	to	confirm	knockouts	have	the	expected	marked	reduction.		Finally,	protein	expression	can	be	measured	using	the	technique	of	western	blot.		This	requires	antibodies	specific	for	the	protein	of	interest.		In	the	case	of	Gαi2,	the	specificity	of	the	antibodies	available	is	not	sufficient	to	differentiate	from	other	Gαi	isoforms;	hence	the	use	of	mRNA	analysis	and	Sanger	sequencing.			RNA	extraction		In	order	to	show	tissue-specific	knockout	of	the	GNAI2	gene	product,	Gαi2,	in	mice	genotyped	as	Gαi2	Flx/Flx	Cre+	(termed	cKOs	hereafter),	hearts,	livers	and	tails	were	harvested	from	four	cKO	mice	and	four	mice	of	wild-type	GNAI2	gene	status	(three	Gαi2	WT/WT	Cre-,	and	one	Gαi2	WT/WT	Cre+).		Mice	were	culled	by	cervical	dislocation,	organs	excised	and	stored	in	RNAlater	(Sigma-Aldrich,	UK)	prior	to	storage	at	-80	°C	pending	RNA	extraction.			This	was	performed	using	RNEasy	Fibrous	Tissue	mini	kit	(Qiagen)	according	to	the	following	product	instructions	(all	reagents	supplied	within	the	kit):		 1. Buffers	and	reagents	prepared	as	per	protocol	2. Approximately	30	mg	of	tissue	was	removed	from	storage	in	RNAlater	3. The	tissue	was	frozen	with	liquid	nitrogen,	and	disruption	was	performed	with	a	mortar	and	pestle.		Homogenisation	was	performed	with	a	needle	and	syringe	in	300	μl	of	Buffer	RLT	4. 590	μl	of	RNAse-free	water	was	added	to	the	lysate.		Then	10	μl	of	proteinase	K	solution	was	added	and	mixed	5. The	mixture	was	incubated	at	55	°C	for	10	minutes	6. It	was	then	centrifuged	for	3	minutes	at	12,500	rpm	7. The	supernatant	was	pipetted	into	a	new	microcentrifuge	tube	8. 450	μl	of	ethanol	(96-100%)	was	added	to	the	cleared	lysate	and	mixed	by	pipetting	9. 700	μl	of	the	sample	was	transferred	to	an	RNeasy	Mini	spin	column	placed	in	a	2	ml	collection	tube.		This	was	centrifuged	for	15	s	at	10,000	rpm.	The	flow-through	was	discarded	10. Step	9	was	repeated	with	the	remainder	of	the	sample	11. 350	μl	of	Buffer	RW1	was	added	to	the	RNeasy	spin	column.		This	was	centrifuged	for	15	s	at	10,000	rpm.		The	flow-through	was	discarded	
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• As	for	WT	allele	but	without	MgCl2	and	with	22.8	μl	water		 1. Heat	lid	to	110	°C	2. 94	°C	for	5	minutes	
	 84	
































































































2.10.2	 Buffer	solutions		The	following	modified	Krebs-Henseleit	buffer	(hereafter	termed	‘Krebs’)	master	solution	was	made	up	prior	to	slice	preparation	on	the	day	of	procedure	(molecular	concentration):	NaCl	6.896	g	(118	mM),	KCl	0.283	g	(3.8	mM),	MgSO4-7H20	0.293	g	(1.19	mM),	NaHCO3	2.1	g	(25	mM),	KH2PO4	0.162	g	(1.19	mM),	D-glucose	0.9	g	(5	mM),	sodium	pyruvate	0.220	g	(2	mM)	were	dissolved	in	1	L	of	distilled	water.				This	‘Calcium-free	Krebs’	solution	was	used	to	produce	the	following	modified	Krebs	solutions:	1. Normal	Krebs	(Ca2+	1.4	mM,	K+	5	mM)		 	 	 	 	 	2. Perfusion-Slicing	Krebs	(Ca2+	0.6	mM,	K+	15	mM,	BDM	(10	mM,	Sigma-Aldrich):	4	°C	3. Resting	Krebs	(same	as	Perfusion-Slicing	Krebs):	21	°C	 	 	 	4. Preparation	Krebs	(Ca2+	1.4	mM,	K+	5	mM,	BDM	10	mM):	21	°C	 	5. Bathing	Krebs	(Ca2+	1.4	mM,	K+	5	mM):	37	°C	 	 	 	
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2.10.4	 Stimulation		Unipolar	stimulation	of	the	slice	was	commenced	straight	away	using	MC_Rack	version	4.5.11	(Multi	Channel	Systems).		An	electrode	at	the	periphery	of	the	MEA	was	selected,	and	the	following	initial	settings	were	used:	a	biphasic	pulse	of	-40	μA	for	1	ms	and	40	μA	for	1	ms	at	a	cycle	length	(CL)	of	1000	ms.		If	no	capture	was	achieved,	stimulation	via	a	different	peripheral	electrode	was	tried.		This	was	repeated	until	capture	was	achieved;	if	necessary,	non-peripheral	electrodes	were	utilised.		If	no	capture	was	achieved	after	15	minutes,	the	slice	was	discarded.		If	stable	capture	was	achieved,	the	stimulation	CL	was	reduced	to	500	ms	after	20-25	minutes	and	threshold	was	determined.		Output	current	was	set	at	twice	diastolic	threshold	in	all	experiments.		After	30-40	minutes,	the	CL	was	reduced	to	250	ms;	often	at	this	stage,	it	was	necessary	to	change	the	stimulating	electrode	due	to	either	lack	of	consistent	capture,	or	EGMs	of	inadequate	quality	to	permit	measurement	of	activation	time	(a	sharp	downstroke	separate	from	the	pacing	stimulus).		Care	was	also	taken	to	avoid	stimulating	such	that	wide	capture	appeared	to	occur,	as	indicated	by	simultaneous	activation	across	the	MEA.		If	the	stimulating	electrode	was	changed,	the	threshold	was	re-determined	and	output	adjusted	accordingly.		The	electrode	was	not	changed	once	the	experiment	proper	had	begun,	i.e.	commencement	of	measurements.			Preconditions	for	continuing	the	experiment	past	this	point	were:		- Consistent	capture	- A	discernible	downward	deflection	within	5	ms	of	the	stimulus	artefact	on	an	electrode	within	400	μM	of	the	stimulating	electrode,	to	allow	measurement	of	local	activation	time	(‘reference	electrode’	signal)	- Increase	in	activation	time	with	increasing	distance	from	the	stimulus	- At	least	two	good	quality	EGMs	≥	600	μM	from	the	reference	electrode					
	 108	






















outcome	variables	were	considered	normal,	a	t-test	with	unequal	variances	was	used.		If	both	assumptions	were	invalid,	the	appropriate	non-parametric	test	was	used,	dependent	on	whether	the	data	were	paired	(Wilcoxon	signed-rank)	or	unpaired	(Wilcoxon	Ranksum/Mann-Whitney	U).			Correlational	analyses	report	Pearson’s	product	moment	coefficient	(r)	unless	otherwise	stated.		Comparison	of	number	of	observations	between	groups	was	performed	with	Fisher’s	Exact	test	unless	otherwise	stated.					MEA	studies		Multilevel	mixed	effects	models	were	employed	to	analyse	repeated	measures	data	after	recommendation	by	a	statistician	due	to	their	advantages	over	repeated	measures	analysis	of	variance	(RM-ANOVA).		These	include	fewer	assumptions,	or	requirement	for	less	strict	adherence	to	them;	the	ability	to	build	in	increasing	hierarchical	complexity	with	‘levels’	of	data	corresponding	to	groupings;	and	the	ability	to	analyse	incomplete	datasets.		With	regard	to	the	assumptions,	the	lack	of	comprehensible	instructions	on	how	to	test	data	for	compound	symmetry	and	sphericity,	and	more	importantly,	what	to	do	if	your	data	do	not	meet	these	assumptions,	made	multilevel	mixed	effects	models	attractive.		Further	considerations	were	that	the	random	effects	component	provides	a	means	of	varying	the	slope	(lines	of	best	fit)	for	each	individual	sample’s	data.			Below	is	an	overview	of	the	steps	involved	in	using	multilevel	models	to	analyse	ERP,	activation	time	and	conduction	velocity	data,	using	variable	drug	concentrations	as	an	exemplar:	i. Input	variables	and	re-shape	to	long	format	ii. Random	intercept	model	with	concentration	as	a	continuous	variable;	store	estimates	iii. Random	slopes	model	with	concentration	as	a	continuous	variable;	store	estimates	iv. Likelihood	ratio	test	to	compare	models	v. If	p<0.05,	use	random	slopes	model;	if	not,	restore	random	intercept	estimates	vi. Check	assumptions	of	normality	of	residuals	and	homoscedasticity	vii. Plot	original	data	and	fitted	lines	for	each	sample	to	visually	check	model	
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WT Het Flx/Flx 1000bp 500bp 














	 cKOs	 Controls			 Heart	Gαi2	-	GAPDH	 Liver	Gαi2	-	GAPDH	 Heart	Gαi2	-	GAPDH	 Liver	Gαi2	-	GAPDH		 	 	 	 	Mean	ΔCt	 4.34	 4.07	 3.56	 3.41		




	 cKOs		 Controls			 Heart	Gαi2	-	GAPDH	 Liver	Gαi2	-	GAPDH	 Heart	Gαi2	-	GAPDH	 Liver	Gαi2	-	GAPDH		 	 	 	 	Mean	ΔCt	 6.67	 5.13	 5.73	 5.99	
	








	 		 Controls	(n=18)		 cKOs	(n=16)		 p-value		 		 (SD	or	IQR)	 (SD	or	IQR)	 		ECG	 HR,	bpm	 675		(71)	 671		(88)	 0.877	
	 PR,	ms	 31.8		(2.0)	 31.8		(2.3)	 0.977		 QRS,	ms	 10.4		(0.7)	 10.1		(0.8)	 0.382		 QTs,	ms	 17.0		(1.4)	 17.5		(1.3)	 0.288		 QTc,	ms	 39.8		(5.9)	 40.9		(4.9)	 0.581		 		 	 	 	Echo	 LVIDd,	mm	 4,0		(0.3)	 3.9		(0.5)	 0.508	
	 LVIDs,	mm	 2.8		(0.4)	 2.6		(0.5)	 0.296		 FS,	%	 31.2		(28.0-35.0)	 33.4		(27.5-39.5)	 0.220		 EF,	%	 58.5		(56.0-65.0)	 62.4		(54.0-71.5)	 0.201		 EndoD,	mm2	 10		(1.6)	 9.8		(1.3)	 0.663		 EndoS,	mm2	 4.5		(1.0)	 4.1		(1.1)	 0.233		 FAC,	%	 55		(5.5)	 59		(7.5)	 0.136		 		 	 	 	HRV	 HR,	bpm	 677		(75)	 670		(86)	 0.796	














	 		 Controls	(n=12)		 cKOs	(n=11)		 p-value		 		 (SD	or	IQR)	 (SD	or	IQR)	 		ECG	 HR,	bpm	 712		(50)	 727		(68)	 0.560	
	 PR,	ms	 31		(2)	 30		(2)	 0.283		 QRS,	ms	 12	(11-13)	 13		(12-14)	 0.092		 QTc,	ms	 48		(8)	 54		(6)	 0.058		 		 	 	 	Echo	 EndoD,	mm2	 12.4		(4.6)	 13.0		(2.8)	 0.711	
	 EndoS,	mm2	 7.9		(4.8)	 9.3		(3.0)	 0.437		 FAC,	%	 41		(17)	 30		(11)	 0.093		 		 	 	 	HRV	 HR,	bpm	 724		(43)	 729		(76)	 0.824	





















































































Time	(mins)	 pH	(solution	1)	 pH	(solution	2)		 	 	0	 7.74	 7.62	5	 7.62	 7.45	10	 7.55	 7.39	25	 7.49	 7.35	
	
Table	11		pH	of	the	modified	Krebs-Henseleit	buffer	solution	during	bubbling	with	carbogen.		Two	preparations	were	assessed:	solution	1	and	2.					







































































































































8.7.1	 Choice	of	experimental	model		A	number	of	experimental	models	and	animals	have	been	used	to	study	cellular	and	tissue	electrophysiology.		These	include,	but	are	not	limited	to,	in	situ	hearts,	isolated	perfused	hearts	(murine,	leporine,	canine,	human),	and	papillary	muscle	preparations.		In	terms	of	recording	electrophysiological	parameters,	this	may	be	achieved	with	multiple	individual	electrodes	including	MAP	electrodes,	multi-electrode	arrays,	and	potentiometric	dyes.		The	MEA	system	utilising	cardiac	tissue	slices	has	several	potential	advantages	(discussed	in	Section	1.9.2).		Amongst	these	are	the	potential	to	obtain	several	slices	from	the	same	heart,	which	in	theory	allows	for	some	control	of	inter-heart	variability.		This	is	also	a	means	of	maximising	experiments	from	each	animal.		In	terms	of	the	possible	measurements	and	time	available,	the	use	of	slices	permitted	pharmacological	testing	with	measurement	of	ERP,	local	activation	time	and	conduction	velocity.			The	alternative	ex	vivo	systems	available	for	measuring	cardiac	electrophysiological	parameters	include,	for	example,	application	of	an	MEA	to	the	surface	of	an	intact	heart	which	is	retrogradely	perfused	via	a	Langendorff	system.		And	potentiometric	(voltage-sensitive)	dyes	can	also	be	perfused	through	the	isolated	heart	or	tissue	to	enable	visualisation	of	depolarisation	and	repolarisation293,294.			Advantages	of	ex	vivo	whole	heart	experiments	include:	- less	tissue	damage:	this	maintains	not	only	viability,	but	also	intercellular	connections	and	conduction	pathways	- 3D	architecture:	though	not	necessarily	an	advantage	with	murine	hearts,	in	large	animals	such	as	humans	transmural	electrophysiological	differences	are	present	and	of	pathophysiological	importance			
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